Sefako Makgatho Health Sciences University (SMU) continues to solidify its reputation as a leader in health sciences research, with its NRF-rated researchers playing a crucial role in shaping the institution’s academic landscape. Among them is Dr Bwalya Angel Witika, a Senior Lecturer and NRF-rated researcher in Pharmaceutical Sciences, whose work in nanomedicine and drug delivery systems is making significant strides.
Witika, a Pharmacist by profession, has an extensive background in drug design, development, and delivery. With over 47 ISI-accredited publications, three book chapters, and an editorial role, his contributions to the field of pharmaceutical sciences are substantial. “My research focuses on developing advanced drug delivery systems, nanomedicines, and functional biomaterials for treating infectious, hereditary, and lifestyle diseases,” he explains.
His interest in pharmaceutical research was sparked by the urgent need for innovative healthcare solutions in Africa. Coming from an academic family, with his father a professor of chemical and mining engineering, he was introduced to the importance of scientific research at an early age. This exposure, coupled with his fascination with molecular medicine, led him to specialise in nanomedicine and drug delivery.
Witika’s research journey began at Rhodes University, where he earned his Master’s and PhD in Pharmaceutics. “One of my biggest challenges was navigating resource limitations and securing collaborations,” he recalls. However, strategic networking and perseverance helped him overcome these hurdles.
Since joining SMU in 2021, Witika has been at the forefront of pioneering nanomedicine research at the university. “The leadership at SMU has been instrumental in my success, providing access to cutting-edge research equipment and fostering a collaborative environment,” he says. His contributions have not gone unnoticed—he recently received the Best Emerging Researcher Award and a prestigious NRF Y2 rating.
Witika’s award-winning research centres on innovative drug delivery systems, including nano drug design and functional biomaterials. One of his most notable achievements is the development of SMU’s first-ever product patent aimed at improving breast cancer and osteoporosis treatment. “Our research enhances treatment efficacy while minimising side effects, ensuring better patient compliance,” he explains.
Beyond academia, Witika’s work is geared towards real-world application. “Our technologies are designed to be affordable and adaptable, particularly for underserved communities,” he notes. Although his research has yet to be translated into practical healthcare solutions, it is progressing towards implementation, with support from industry partners.
Witika’s research is highly collaborative, involving partnerships with institutions across five countries. “I have secured grants with collaborators from Northern Ireland, France, and Brazil while maintaining strong ties with local universities,” he says. His work in interdisciplinary research, particularly in nanomedicines and biomaterials, benefits from collaborations with chemists, biologists, and engineers.
Looking ahead, he envisions his research evolving towards personalised medicine and artificial intelligence-driven drug delivery. “I recently secured funding to collaborate with a world-leading researcher in microneedle technology in Northern Ireland, which will open new research avenues,” he reveals. His team is also embarking on an ambitious project for HIV prevention in women, which could revolutionise long-term, cost-effective prevention methods.
For aspiring researchers, Witika emphasises the importance of persistence and collaboration. “Building a strong network of mentors and maintaining adaptability are key to success,” he advises. He also highlights the role of funding in advancing research and calls for greater institutional support for emerging researchers.
As SMU continues to drive excellence in health sciences research, Witika’s work illustrates the university’s commitment to innovation. “I am dedicated to pushing the boundaries of pharmaceutical sciences and mentoring the next generation of researchers,” he concludes.
By Tumelo Moila
